Related Experiment Video
Updated: Jun 11, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion
Pierre Fenaux1, David Bowen, Norbert Gattermann
1Hôpital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France. pierre.fenaux@avc.aphp.fr
Abstract:
Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.